ArticleJournal of medical imaging and radiation oncology2026
Elderly Glioblastoma: Long-Course Versus Short-Course Chemoradiotherapy: A Regional New Zealand Retrospective Review.
Article in Journal of medical imaging and radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionElderly patients make up a large proportion of those diagnosed with glioblastoma. There are multiple treatment options available for elderly patients including conventional and hypofractionated chemoradiotherapy, chemotherapy monotherapy and best supportive care; therefore, management decision-making can be complex. This retrospective study aims to compare overall survival (OS) and review prognostic factors in patients aged 65 and above who received either long-course or short-course chemoradiotherapy in regional New Zealand.
methodA regional New Zealand Neurosurgical database identified patients aged ≥ 65 who received the EORTC-NCIC long-course radiotherapy (60Gy in 30 fractions) or the NCIC-CTG short-course radiotherapy (40Gy in 15 fractions), both with concomitant and adjuvant temozolomide.
results76 patients diagnosed between 2006 and 2018 were included for analysis. Median OS for those receiving long-course (n = 59) was 15.4 months and for those receiving short-course (n = 17) was 16.9 months. 12-month estimated OS probability was 73% for long-course and 65% for short-course. 24-month estimated OS probability was 22% for long-course and 18% for short-course. There was no statistically significant difference in OS between the two treatment regimes. In a median-regression testing analysis there was insufficient evidence to show that extent of surgical resection, timing of radiotherapy from surgery and use of steroids during radiotherapy were prognostic factors. MGMT methylation status was seldom available for patients during this time.
conclusionIn this study, median OS of elderly patients receiving long-course or short-course chemoradiotherapy was similar. Short-course chemoradiotherapy should routinely be considered in all elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.